Suven Life Sciences misses target for Alzheimers molecule SUVN 502

CNBC-TV18 2019-12-02

Views 460

Suven Life Sciences has missed their target for SUVN 502 - a molecule which they were banking on for Alzheimers and outlicensing opportunity. Venkat Jasti, chairman and CEO of Suven Life Sciences shared more details and the future course of action.

Share This Video


Download

  
Report form